Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company is headquartered in Gaithersburg, Maryland and currently employs 52 full-time employees. The company went IPO on 2005-10-06. The Company’s lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and non-alcoholic steatohepatitis (NASH). The company is also developing HepTcell, an immunotherapeutic agent designed to achieve a functional cure for chronic hepatitis B. The firm has initiated a Phase II clinical trial of HepTcell and is in Phase II and Phase I clinical development with pemvidutide for multiple indications. The company is conducting its Phase II clinical trial of HepTcell in the United States, United Kingdom, Canada, Germany Spain and Thailand. The Company’s wholly owned subsidiaries include Altimmune, LLC, Altimmune UK, Limited, Spitfire Pharma, LLC and Altimmune AU Pty, Limited.